Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Pathogen RNA refers to the diverse set of ribonucleic acid molecules produced by viruses, bacteria, and other infectious agents, serving as the blueprint for protein synthesis and, in many viruses, the primary genetic material. These molecules include messenger RNA (mRNA) for protein production, ribosomal RNA (rRNA) for structural and catalytic functions in the ribosome, and various non-coding RNAs (ncRNAs) that regulate virulence and metabolic adaptation. As a therapeutic target, pathogen RNA is highly significant; many traditional antibiotics, such as aminoglycosides and oxazolidinones, exert their effects by binding directly to bacterial rRNA to disrupt translation. Modern therapeutic strategies have expanded to include antisense oligonucleotides (ASOs) and siRNAs designed to specifically degrade viral transcripts, as well as small molecules targeting highly structured RNA motifs like riboswitches or viral frameshifting elements. Despite its potential, targeting pathogen RNA requires overcoming significant hurdles, including ensuring high selectivity to avoid host toxicity and addressing the rapid evolutionary capacity of pathogens to develop resistance through sequence mutations.
Drugs targeting pathogen RNA typically function by inhibiting translation through binding to ribosomal RNA (rRNA), inducing RNA degradation via RNase H-mediated cleavage (antisense oligonucleotides), or causing steric hindrance of replication and splicing. Nucleoside analogs may also be incorporated into the growing RNA strand to cause chain termination or lethal mutagenesis. Additionally, small molecules can modulate riboswitches to repress essential gene expression in bacteria.
9 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Pathogen ribonucleic acid (RNA) (Pathogen RNA).